ライフサイエンスコーパス: soluble guanylyl cyclase

1 iven by the hsp90 chaperone machinery and by soluble guanylyl cyclase.

2 I)PPIX remains four coordinate when bound to soluble guanylyl cyclase.

3 Four-coordinate metalloporphyrins activate soluble guanylyl cyclase.

4 quires endothelial nitric oxide synthase and soluble guanylyl cyclase.

5 old rats do not express the beta subunit of soluble guanylyl cyclase.

6 receptors act by NO-mediated stimulation of soluble guanylyl cyclase.

7 endothelial nitric oxide synthase (NOS) and soluble guanylyl cyclase.

8 signaling pathways mediated by a CO receptor soluble guanylyl cyclase.

9 oprotective effect is mediated by activating soluble guanylyl cyclase.

10 ansfer of NO-ferroheme and activation of apo-soluble guanylyl cyclase.

11 smaller extent, by the direct stimulation of soluble guanylyl cyclase.

12 ex, which, among other functions, stabilizes soluble guanylyl cyclase.

13 d suppression of NF-kappaB and activation of soluble guanylyl cyclase.

14 ERK pathway and the subsequent activation of soluble guanylyl cyclase.

15 is via endothelial nitric-oxide synthase and soluble guanylyl cyclase.

16 by maintaining the synaptic localization of soluble guanylyl cyclase.

17 show similarity to the regulatory domain of soluble guanylyl cyclases.

18 An inhibitor of soluble guanylyl cyclase, (1)H-(1,2,4)oxadiazolo(4,3-a)q

19 nor was partially blocked by an inhibitor of soluble guanylyl cyclase, 1H-[1,2,4]oxadiazolo[4,3, -a]q

20 Inhibition of the soluble guanylyl cyclase abolished the effect of L-argin

21 2 receptors to stimulate cGMP production via soluble guanylyl cyclase activation and absorption throu

22 vailability of NO would be too low to elicit soluble guanylyl cyclase activation in the presence of b

23 play an important role in NO generation and soluble guanylyl cyclase activation under hypoxic condit

24 With the addition of nitrite, soluble guanylyl cyclase activation was significantly hi

25 transient cGMP response upon particulate or soluble guanylyl cyclase activation, while the cGMP resp

26 on of CO, we examined the potency of CO as a soluble guanylyl cyclase activator.

27 measured in distal human PASMCs treated with soluble guanylyl cyclase activators (nitric oxide donors

28 and cAMP-dependent mechanism for modulating soluble guanylyl cyclase activity in pituitary cells.

29 ell as beta1-sGC protein content, and impair soluble guanylyl cyclase activity.

30 (S-nitroso-N-acetyl-DL-penicillamine) and a soluble guanylyl cyclase agonist (YC-1) mimicked AMPA ef

31 nserved region (X-peptide) of the Drosophila soluble guanylyl cyclase alpha-subunit (SGCalpha).

32 GUCY1A3 encodes the alpha1 subunit of soluble guanylyl cyclase (alpha1-sGC), and CCT7 encodes

33 3-a]quinoxalin-1-one (ODQ), an inhibitor of soluble guanylyl cyclase, also blocked the effects of ni

34 Dual stimulation of soluble guanylyl cyclase and inhibition of PDE5 activiti

35 Carbon monoxide (CO) is an activator of soluble guanylyl cyclase and is implicated as a neuronal

36 es cGMP signaling, was also inhibited by the soluble guanylyl cyclase and KATP channel blockers.

37 uinea pig cochlea, by means of activation of soluble guanylyl cyclase and protein kinase G.

38 The stimulatory role of NOS is mediated by soluble guanylyl cyclase and results from a cGMP-depende

39 Nitric oxide (NO) stimulates soluble guanylyl cyclase and, thus, enhances cyclic guan

40 of Dictyostelium discoideum, a heterodimeric soluble guanylyl cyclase, and a homodimeric membrane gua

41 te transporters, nitric oxide (NO) synthase, soluble guanylyl cyclase, and ATP-sensitive potassium (K

42 esent study, we determined the role of cGMP, soluble guanylyl cyclase, and protein kinase G in the po

43 and by sodium nitroprusside, an activator of soluble guanylyl cyclase, and was potentiated by a cGMP-

44 ts is due to the lack of the beta subunit of soluble guanylyl cyclase, and we speculate that this def

45 Signaling is both soluble guanylyl cyclase- and phosphodiesterase 6-depend

46 ups in both Ni(II)- and Cu(II)-reconstituted soluble guanylyl cyclase are consistent with a substanti

47 Conventional soluble guanylyl cyclases are heterodimeric enzymes that

48 The mechanism was due to the activation of soluble guanylyl cyclase because 8-bromo-cyclic GMP acti

49 ffects of CO in this study were mediated via soluble guanylyl cyclase, because 1H-(1,2,4)oxadiazole (

50 NO targets cell proteins such as soluble guanylyl cyclase, but its detrimental effects ar

51 by N(G)-nitro-L-arginine methyl ester and of soluble guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3,-a]

52 d receptors stimulate nitric oxide-sensitive soluble guanylyl cyclase by increasing intracellular Ca(

53 Blockade of soluble guanylyl cyclase by ODQ (1H-[1,2,4] oxadiazolo[4

54 tro-L-arginine methyl ester) and blockade of soluble guanylyl cyclase (by ODQ; 1H-1,2,4-oxadiazolo[4,

55 MP analog 8-bromo-cGMP, as well as by the NO-soluble guanylyl cyclase-cGMP signaling inhibitor thromb

56 ulator BAY-41-2272 converts the CO adduct of soluble guanylyl cyclase (CO-sGC) enzyme from a low- to

57 ese data support a model where activation of soluble guanylyl cyclase correlates with the absence of

58 nisms through which NO generally acts is the soluble guanylyl cyclase-cyclic GMP (sGC-cGMP) pathway.

59 d protein modification, biologically through soluble guanylyl-cyclase-dependent modulation of the MMP

60 , we have identified a link between impaired soluble-guanylyl-cyclase-dependent nitric oxide signalli

61 global elevation of cGMP after activation of soluble guanylyl cyclase does not relax the muscle.

62 .By blocking the activity of NO synthase and soluble guanylyl cyclase enzymes after training, we prov

63 , which subsequently activates smooth muscle soluble guanylyl cyclase for vasodilation.

64 Previously characterized soluble guanylyl cyclases form alpha-beta heterodimers t

65 ht to be mediated by the action of NO on the soluble guanylyl cyclase (GC) in the smooth muscle and s

66 Soluble guanylyl cyclase (GC) is a heterodimer that is a

67 ric oxide synthase (NOS) and the NO receptor-soluble guanylyl cyclase (GC), the activation of which l

68 eviously demonstrated that the NO-stimulated soluble guanylyl cyclase (GC1), which produces cGMP, als

69 After stimulation with nitric oxide, soluble guanylyl cyclase generates cGMP, which induces v

70 iven pRb hyperphosphorylation occurs through soluble guanylyl cyclase/guanosine 3',5'-cyclic monophos

71 The three Drosophila atypical soluble guanylyl cyclases, Gyc-89Da, Gyc-89Db, and Gyc-8

72 contains three genes that code for atypical soluble guanylyl cyclases: Gyc-88E, Gyc-89Da, and Gyc-89

73 Recently, a separate class of soluble guanylyl cyclases has been identified that are o

74 Nitric oxide (NO) activates soluble guanylyl cyclase in smooth muscle cells to induc

75 The distribution of soluble guanylyl cyclase in the brain of the locust Schi

76 uanylyl cyclases and of 7 gcy genes encoding soluble guanylyl cyclases in the complete genome sequenc

77 imulated fluid absorption was blocked by the soluble guanylyl cyclase inhibitor 1-H-[1,2,4]oxadiazolo

78 n viable cells, which was not blocked by the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[

79 romo-cyclic GMP activated PI3 kinase and the soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[

80 this lusitropic effect was attenuated by the soluble guanylyl cyclase inhibitor 1H:-[1,2,4]oxadiazolo

81 Porcine leaflets exposed to the soluble guanylyl cyclase inhibitor ODQ increased osteoca

82 ,4)oxadiazole (4,3-alpha) quinoxaline-1-one (soluble guanylyl cyclase inhibitor) completely reversed

83 e to anoxic conditions and is blocked by the soluble guanylyl cyclase inhibitor, 1H-[1,2,4]oxadiazolo

84 These effects were inhibited by LY 83583, a soluble guanylyl cyclase inhibitor, and mimicked by 8-Br

85 Furthermore, both the soluble guanylyl cyclase inhibitor, ODQ, and the specifi

86 -1-one (P<0.05 and P<0.001, respectively), a soluble guanylyl cyclase inhibitor.

87 lation and are not affected by infusion of a soluble guanylyl cyclase inhibitor.

88 ,2,4]-oxadiazolo-[4,3-a]quinoxalin-1-one) (a soluble guanylyl cyclase-inhibitor, Rp-8-(4-chlorophenyl

89 he presence of various phosphodiesterase and soluble guanylyl cyclase inhibitors, confirming that G(s

90 We have identified a novel soluble guanylyl cyclase isoform from the nervous system

91 GMP; though H(2)S does not directly activate soluble guanylyl cyclase, it maintains a tonic inhibitor

92 Inhibitors of soluble guanylyl cyclase, LY 85353 and methylene blue, a

93 by the additional presence of inhibitors of soluble guanylyl cyclase (LY83583) or protein kinase G (

94 xpression of Foxp3 in MBP-primed T cells via soluble guanylyl cyclase-mediated production of cGMP.

95 ther and how cardiomyocyte NO-sensitive GC1 (soluble guanylyl cyclase) mediates female-specific, adap

96 icroM 8-Bromo-cGMP), and (iii) inhibition of soluble guanylyl cyclase (ODQ (1H-[1,2,4,]oxadiazolo(4,3

97 e (NO) synthesis, L-NNA, and an inhibitor of soluble guanylyl cyclase, ODQ, greatly enhanced colonic

98 Furthermore, inhibition of the NO target soluble guanylyl cyclase or of the cGMP effector kinase

99 Inhibitors of soluble guanylyl cyclase or PKG decreased activity of th

100 agents that release nitric oxide, stimulate soluble guanylyl cyclase, or activate cGMP-dependent pro

101 e conclude that NO production, activation of soluble guanylyl cyclase, or changes in intracellular cG

102 of NO in suppressing Foxp3(+) Tregs via the soluble guanylyl cyclase pathway.

103 rom digenic mutation carriers contained less soluble guanylyl cyclase protein and consequently displa

104 eroxynitrite scavengers or inhibitors of the soluble guanylyl cyclase/protein kinase G pathway.

105 ors of phosphodiesterase 5 or stimulators of soluble guanylyl cyclase rapidly enhanced multiple prote

106 e synthase (eNOS) by directly activating its soluble guanylyl cyclase receptor, rescued blood vessel

107 n-1-one, inhibitors of NO synthase (NOS) and soluble guanylyl cyclase, respectively, abolished tadala

108 sine 3',5'-cyclic monophosphate ([cGMP]i) by soluble guanylyl cyclase, resulting in fast onset and lo

109 , we demonstrate the effect of NO donors and soluble guanylyl cyclase (sGC) activators in differentia

110 ) derivatives have been studied as potential soluble guanylyl cyclase (sGC) activators.

111 It is shown here that soluble guanylyl cyclase (sGC) activity is required for

112 y firmly established endogenous modulator of soluble guanylyl cyclase (sGC) activity, but physiologic

113 Nitric oxide (NO) stimulates soluble guanylyl cyclase (sGC) activity, leading to elev

114 2667 derivatives and tested their effects on soluble guanylyl cyclase (sGC) activity.

115 e isoforms (ACs 1-9), a structurally related soluble guanylyl cyclase (sGC) and a soluble AC (sAC).

116 VSMCs, expressing soluble guanylyl cyclase (sGC) and PKG-I isoforms showed

117 indicates that the functional properties of soluble guanylyl cyclase (sGC) are affected not only by

118 e have identified the alpha1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regul

119 Heme insertion is key during maturation of soluble guanylyl cyclase (sGC) because it enables sGC to

120 of recombinant nitric oxide (NO)-stimulated soluble guanylyl cyclase (SGC) by Ca2+ was demonstrated.

121 r diseases with the oxidation of the heme of soluble guanylyl cyclase (sGC) critically implicated in

122 Nitric oxide (NO)-unresponsive forms of soluble guanylyl cyclase (sGC) exist naturally and in di

123 Although soluble guanylyl cyclase (sGC) functions in an environme

124 nce that treatment with NO donors stimulates soluble guanylyl cyclase (sGC) in the MCC, and as a resu

125 9A mRNA expression closely resembles that of soluble guanylyl cyclase (sGC) in the rat brain, suggest

126 l-L-arginine (NMMA); 300 or 500 microM) or a soluble guanylyl cyclase (sGC) inhibitor (1H-[1,2,4]oxad

127 ase in cell volume that was abolished by the soluble guanylyl cyclase (sGC) inhibitor 1H-[1,2,4]oxadi

128 -nitro-L-arginine methyl ester; 30 mg/kg), a soluble guanylyl cyclase (sGC) inhibitor [1H-(1, 2, 4) o

129 nt with either a nitric oxide scavenger or a soluble guanylyl cyclase (sGC) inhibitor diminished the

130 Soluble guanylyl cyclase (sGC) is a cytosolic enzyme pro

131 The enzyme soluble guanylyl cyclase (sGC) is a heterodimer composed

132 Soluble guanylyl cyclase (sGC) is a heterodimeric enzyme

133 Soluble guanylyl cyclase (sGC) is a key component of NO-

134 Heterodimeric alphabeta soluble guanylyl cyclase (sGC) is a recognized receptor

135 Diatomic ligand discrimination by soluble guanylyl cyclase (sGC) is paramount to cardiovas

136 Soluble guanylyl cyclase (sGC) is the main receptor for

137 Soluble guanylyl cyclase (sGC) is the major cellular rec

138 Soluble guanylyl cyclase (sGC) is the principal receptor

139 Soluble guanylyl cyclase (sGC) is the receptor for nitri

140 e of nitric oxide (NO) in the stimulation of soluble guanylyl cyclase (sGC) is well established, but

141 ts of cGMP levels in this pathway, including soluble guanylyl cyclase (sGC) itself, the NO -activated

142 of cAMP and cGMP in the above effects using soluble guanylyl cyclase (sGC) or adenylate cyclase (AC)

143 have shown that the levels of expression of soluble guanylyl cyclase (sGC) or cGMP-dependent protein

144 Soluble guanylyl cyclase (sGC) plays an important role i

145 iated by nitric oxide (NO), which stimulates soluble guanylyl cyclase (sGC) production of the second

146 blots for endothelial NO synthase (eNOS) and soluble guanylyl cyclase (sGC) revealed reduced eNOS exp

147 In this study, we identified enhanced soluble guanylyl cyclase (sGC) signaling as a mechanism

148 e monophosphate (cGMP) synthesis by forms of soluble guanylyl cyclase (sGC) that do not respond to NO

149 The NO receptor soluble guanylyl cyclase (sGC) was detected immunocytoch

150 pression of the alpha1 and beta1 subunits of soluble guanylyl cyclase (sGC) was directly and specific

151 the alpha(1) and beta(1) subunits of murine soluble guanylyl cyclase (sGC) were determined.

152 cular and neuronal systems via activation of soluble guanylyl cyclase (sGC), a heme-containing hetero

153 s in the brain largely through activation of soluble guanylyl cyclase (sGC), a heterodimer comprised

154 s in the brain largely through activation of soluble guanylyl cyclase (sGC), a heterodimer comprising

155 1A3, which encodes the alpha1 subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitr

156 They were tested for activation of soluble guanylyl cyclase (sGC), a key enzyme in the NO/c

157 Soluble guanylyl cyclase (sGC), a key protein in the NO/

158 proximately 9% contained the beta subunit of soluble guanylyl cyclase (sGC), a major target of NO.

159 of neuronal nitric oxide synthase (nNOS) and soluble guanylyl cyclase (sGC), and can be mimicked by t

160 multiprotein complexes with NMDA receptors, soluble guanylyl cyclase (sGC), and PSD95.

161 Whereas NO and its receptor, soluble guanylyl cyclase (sGC), are emerging as key medi

162 tion of the major downstream effector of NO, soluble guanylyl cyclase (sGC), in the superficial dorsa

163 tion of the major downstream effector of NO, soluble guanylyl cyclase (sGC), is very limited.

164 by localizing the expression and activity of soluble guanylyl cyclase (SGC), its principal molecular

165 ignaling through activation of its receptor, soluble guanylyl cyclase (sGC), leading to elevation of

166 NO-sensitive soluble guanylyl cyclase (sGC), one of the best characte

167 ,3-a]quinoxalin-1-one (ODQ), an inhibitor of soluble guanylyl cyclase (sGC), or Rp-8-Br-cGMP, an inhi

168 in the presence of inhibitors selective for soluble guanylyl cyclase (sGC), PKG, calmodulin, CaMKII

169 ted optic nerve, nitric oxide (NO) activates soluble guanylyl cyclase (sGC), resulting in a selective

170 h structural homology to the beta subunit of soluble guanylyl cyclase (sGC), suggesting a NO sensing

171 n yet is homologous to the central region in soluble guanylyl cyclase (sGC), the main receptor for ni

172 he molecular mechanism of desensitization of soluble guanylyl cyclase (sGC), the NO receptor, has lon

173 Soluble guanylyl cyclase (sGC), the principle "receptor"

174 We here report that soluble guanylyl cyclase (sGC), which in turn produces c

175 clinically vasoactive through stimulation of soluble guanylyl cyclase (sGC), which produces the secon

176 tudies determined that the nitric oxide (NO)-soluble guanylyl cyclase (sGC)-cGMP pathway plays a sign

177 tly increased in cells that had a functional soluble guanylyl cyclase (sGC)-cGMP signaling pathway an

178 onducted to determine whether NO activates a soluble guanylyl cyclase (sGC)-cyclic guanosine monophos

179 ta(3)-adrenoceptors (beta(3)-ARs) coupled to soluble guanylyl cyclase (sGC)-dependent production of t

180 ough activation of the heterodimeric enzyme, soluble guanylyl cyclase (sGC).

181 tension is attributed to reduced activity of soluble guanylyl cyclase (sGC).

182 nzyl indazole] is an allosteric activator of soluble guanylyl cyclase (sGC).

183 phosphate (cGMP) subsequent to activation of soluble guanylyl cyclase (sGC).

184 d in the incorporation of heme into iNOS and soluble guanylyl cyclase (sGC).

185 osphate (cGMP) production by the NO receptor soluble guanylyl cyclase (sGC).

186 cGMP production by the heterodimeric enzyme soluble guanylyl cyclase (sGC).

187 is by activating its intracellular receptor, soluble guanylyl cyclase (sGC).

188 tensity light source, to activate the enzyme soluble guanylyl cyclase (sGC).

189 to link organic nitrate to the activation of soluble guanylyl cyclase (sGC).

190 link of organic nitrate to the activation of soluble guanylyl cyclase (sGC).

191 s that investigated the regulation of the NO/soluble guanylyl cyclase (sGC)/cGMP pathway by estrogeni

192 We compared the NO/soluble guanylyl cyclase (sGC)/cGMP pathway in human gli

193 e analyzed the role of the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cGMP/cGMP-dependent prote

194 lex with glutamate NMDA receptors (NMDA-Rs), soluble guanylyl cyclase (sGC, the NO receptor), and PSD

195 y activates a pool of oxidized and heme-free soluble guanylyl cyclase (sGC; see the related article b

196 ked whether the classical, nitric oxide (NO)-soluble guanylyl-cyclase (sGC)-cGMP pathway could modula

197 Nitric oxide (NO)-NO-sensitive (soluble) guanylyl cyclase (sGC)-cyclic guanosine monopho

198 oxide (NO) receptor (alpha1.beta1 isoform of soluble guanylyl cyclase, sGC) is not known.

199 perties of NO synthase (NOS), as well as the soluble guanylyl cyclases (sGCs), which are the best cha

200 Significance: Soluble guanylyl cyclase signaling inhibits castration-r

201 (ODQ, 5-20 microM), a selective inhibitor of soluble guanylyl cyclase, suppressed spontaneous swimmin

202 This is the first demonstration of a soluble guanylyl cyclase that is activated in response t

203 can be achieved by activating the endogenous soluble guanylyl cyclase that produces cGMP.

204 Immunoreactivity for soluble guanylyl cyclase (the NO receptor) was at high l

205 Soluble guanylyl cyclase, the best characterized target

206 eptor-type guanylyl cyclases, the eukaryotic soluble guanylyl cyclases, the unicellular eukaryotic an

207 ion as coneurotransmitters, both stimulating soluble guanylyl cyclase to cause smooth muscle relaxati

208 h both NO and carbon monoxide (CO) stimulate soluble guanylyl cyclase to form cGMP, NO also S-nitrosy

209 o not appear to be mediated by activation of soluble guanylyl cyclase to produce cGMP, as these cells

210 through NO synthases, over interaction with soluble guanylyl cyclase, to eventual disposal as nitrit

211 Whereas soluble guanylyl cyclase was expressed at the same level

212 8-bromo-cGMP, indicating that activation of soluble guanylyl cyclase was involved.

213 on the ability of NO to access its receptor, soluble guanylyl cyclase, was explored by measuring cGMP

214 GC, indicating that particulate rather than soluble guanylyl cyclases were involved in iNOS inductio

215 ed formation of NO species and activation of soluble guanylyl cyclase, where xanthine oxidoreductase

216 M, SNP effects are probably mediated through soluble guanylyl cyclase, whereas in Sph the CNP effects

217 Although soluble guanylyl cyclase (which generates cyclic guanosi

218 ons in the brain resembling localizations of soluble guanylyl cyclase, which is activated by CO.

219 ignal via cGMP that is generated by a NO and soluble guanylyl cyclase, while bradykinin B(2) receptor

220 evel NO signals for activating its receptor, soluble guanylyl cyclase, whilst avoiding adverse effect

221 butenyl)-L-ornithine (L-VNIO, 100 microM) or soluble guanylyl cyclase with 1H-[1, 2, 4]oxadiazolo[4,

222 osis was not attenuated by the inhibition of soluble guanylyl cyclase with ODQ, nor could apoptosis b

223 sphodiesterase inhibitors, by stimulation of soluble guanylyl cyclase with YC-1 or with exogenous dib